BrainsWay (ADR)

BrainsWay reported revenue of $17.1 million in Q2 2026, beating analysts’ estimate of $16.31 million; adjusted earnings per share were $0.07, in line with expectations. The company raised its 2026 revenue guidance to $68–70 million and recorded revenue growth of 35% year over year along with more than a fourfold increase in operating income. Gross margin remained steady at 75%, adjusted EBITDA was positive for the twelfth consecutive quarter, and the installed system base rose to around 1,950 units. Management cites strong demand for Deep TMS and the SWIFT protocol, as well as reimbursements covering about 57 million insured people, as drivers. » More on de.investing.com

BrainsWay has acquired a $3 million minority stake in Radial Health as part of a Series A financing round. Radial operates a network of brain-medicine clinics and develops clinical infrastructure, reimbursement tools, and an AI-supported decision platform for non-invasive therapies such as Deep TMS. The capital will be used to expand clinical presence, strengthen the technology platform and evaluate M&A opportunities; BrainsWay describes the investment as part of a strategy to acquire minority stakes in mental health care providers. » More on de.investing.com

A growing number of US insurers, including Optum/United Behavioral Health, have allowed psychiatric nurse practitioners in full-practice states since the end of 2025 to prescribe, supervise and administer transcranial magnetic stimulation (TMS) for commercial plans covering about 34.8 million enrollees. Other payers and providers such as First Coast, National Government Services, Novitas, the VA and TRICARE West have introduced similar reimbursement models, subject to regulatory requirements. BrainsWay sees this as an opportunity to improve access to deep TMS and shorten waiting times; the stock reacted positively and is trading near its 52-week high after a 258% gain last year. » More on de.investing.com